After analyzing clinical outcomes of 83 patients with nasopharyngeal carcinoma receiving CDDP-based therapies, we also observed that high expression levels of MGMT in tumor specimens predict worse survival outcomes. The gene discussed is MGMT; the disease is neoplasm.